You are here

  • Home
  • Archive
  • Volume 80, Issue 8
  • Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

Article metrics

Article menu
XML
Spondyloarthritis
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)

 

Online download statistics by month:

Online download statistics by month: May 2021 to August 2023

AbstractFullPdf
May 202112551241526
Jun 2021545545183
Jul 2021977977240
Aug 2021428423197
Sep 2021231226143
Oct 2021220213127
Nov 202117417087
Dec 202114914560
Jan 202213913063
Feb 202213012859
Mar 202216515582
Apr 202212111673
May 202216516886
Jun 202215415474
Jul 202212612446
Aug 202212512659
Sep 202213213467
Oct 202213413041
Nov 202211711543
Dec 2022838139
Jan 202310110083
Feb 202312111761
Mar 2023928831
Apr 2023625531
May 20231009662
Jun 20231059959
Jul 2023545335
Aug 2023615431
Total626661632688